Drug Analysis: Advair

  • ID: 4489117
  • Drug Pipelines
  • 35 pages
  • Datamonitor Healthcare
1 of 4
Drug Overview

Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). The drug has anti-inflammatory and bronchodilatory effects on patients with asthma. It is administered twice daily through a dry powder inhaler device called Advair Diskus, or a pressurized metered-dose inhaler device known as Advair hydrofluoroalkane (HFA).
Note: Product cover images may vary from those shown
2 of 4
1 Product Profiles
  • Advair: Asthma
  • Advair: Chronic obstructive pulmonary disease (COPD)
List of Figures
Figure 1: Advair for asthma - SWOT analysis
Figure 2: The author’s drug assessment summary of Advair in asthma
Figure 3: The author’s drug assessment summary of Advair in asthma
Figure 4: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Advair for COPD - SWOT analysis
Figure 6: Drug assessment summary of Advair for COPD
Figure 7: The author’s drug assessment summary of Advair for COPD

List of Tables
Table 1: Advair drug profile
Table 2: Advair Diskus pivotal trial data in asthma
Table 3: Advair HFA pivotal trial data in asthma
Table 4: Advair late-phase trial data in asthma
Table 5: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 6: Advair drug profile
Table 7: Overview of pivotal trial data for Advair Diskus in COPD
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • GlaxoSmithKline
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll